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Actin cytoskeletal control during epithelial
to mesenchymal transition: focus on the
pancreas and intestinal tract
H T Morris1 and L M Machesky*,1
1The CRUK Beatson Institute for Cancer Research and University of Glasgow College of Medical, Veterinary and Life Sciences,
Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
The formation of epithelial tissues allows organisms to specialise and form tissues with diverse functions and compartmentalised
environments. The tight controls on cell growth and migration required to maintain epithelia can present problems such as the
development and spread of cancer when normal pathways are disrupted. By attaining a deeper understanding of how cell
migration is suppressed to maintain the epithelial organisation and how it is reactivated when epithelial tissues become
mesenchymal, new insights into both cancer and development can be gained. Here we discuss recent developments in our
understanding of epithelial and mesenchymal regulation of the actin cytoskeleton in normal and cancerous tissue, with a focus on
the pancreas and intestinal tract.
Epithelia are highly organised sheets of cells that serve to form a
barrier between external and internal spaces in tissues. They are
important for the formation of tubes and the creation of a luminal
space where the internal environment can be rendered distinct from
the outside world. Epithelial specialisation arose when eukaryotic
organisms committed to being multicellular and having functionally
specialised tissues, rather than just growing as colonies of more or
less identical clonal cells. Epithelial cells are polarised with respect to
top and bottom, as well as within the plane of the tissue. Epithelial
cells form junctions with their neighbours, involving specialised
cytoskeletal protein assemblies. While metazoans have the clearest
commitment to epithelial specialisation, it is interesting that
epithelial-associated junctional proteins have been found in more
ancient organisms and structures resembling epithelia have been
described for example in the social amoeba Dictyostelium discoideum
(Dickinson et al, 2011). Cancers arising in epithelial tissues are
known as carcinomas and much effort has been devoted to
unravelling the molecular programmes that occur during formation
and progression of carcinomas. One of the most well-studied
features of carcinomas, associated with increased aggressiveness and
metastatic spread, is the loss of epithelial integrity and specialisation,
called epithelial to mesenchymal transition or EMT.
EMT results in loss of features characteristic of epithelial
cells – cell–cell adhesions, polarity and amotility and acquisition of
a mesenchymal phenotype – spindled shape, motility and ability to
invade. These phenotypic changes are accompanied by a loss of
epithelial cell markers such as E-cadherin and increased expression
of mesenchymal markers such as N-cadherin, vimentin and
fibronectin (Figure 1).
EMT was first described in the early 1980s (Greenburg and
Hay, 1982) but was termed as epithelial–mesenchymal transfor-
mation. This was later amended to epithelial–mesenchymal
transition, to reflect the fact that the changes are reversible by
mesenchymal–epithelial transition (MET). EMT is crucial to
many of the normal developmental processes of metazoa. For
example, in mammals, the early embryo forms as a ball of
epithelial-like cells and must undergo EMT to invade and grow in
the uterus (a process known as implantation). There has been
much debate about how to define EMT; for example, should cells
that have developed some mesenchymal features but still retain
some epithelial ones be classed as having undergone EMT, or
does this represent ‘partial’ EMT? This remains a subject of
continuing controversy, which we will not touch on here. In 2008,
three types of EMT were defined at a meeting of experts at Cold
Spring Harbor Laboratory (Kalluri and Weinberg, 2009; Zeisberg
and Neilson, 2009). Although this was by no means the end of the
ongoing discussions about how to define EMT, we believe that it
forms a useful basis for discussion for this review and a starting
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point for gaining a deeper understanding of EMT in development
and cancer:
Type 1 EMT: this is the ‘normal’ process of transition of
epithelial cells to a mesenchymal state during implantation and
embryonic development, as part of the processes of gastrulation
and neural crest formation.
Type 2 EMT: this EMT programme occurs in response to
inflammation and is integral to the processes of tissue repair,
regeneration and in cases where the inflammatory response is
prolonged, fibrosis. This type can also be induced in cancer.
Type 3 EMT: this EMT programme is observed in neoplastic
tumour-forming cells as a part of tumour dedifferentiation. Once
having undergone EMT, tumour cells are able to invade and
migrate to distant sites where they may establish metastases – by
definition, conferring properties of malignancy on these cells. This
can be accompanied by MET whereby the metastatic tumour
nodule once again takes on epithelial characteristics.
For transitions between epithelial and mesenchymal states, cells
need to tightly control their motility programmes. Control happens at
multiple levels, including gene expression, post-translational mod-
ifications and reorganisation of the actin cytoskeleton. Here we
discuss EMT during development and in cancer of the pancreas and
intestinal tract and we highlight some of the actin cytoskeletal changes
that occur during EMT and our emerging understanding of how the
cytoskeleton and motility are regulated during these processes.
REPROGRAMMING DURING EMT
All types of EMT are driven by a combination of intrinsic
programming of cells and environmental factors, such as signals
from the stroma. Two of the most important signalling pathways
driving EMT are the transforming growth factor beta (TGFb) and
Wnt pathways (Tam and Weinberg, 2013). Other pathways include
receptor tyrosine kinase, Notch and Hedgehog signalling pathways.
These signalling pathways trigger a reprogramming of gene
expression patterns via various methods, including transcriptional
changes, alternative splicing pathways and altered expression of
micro-RNA (miR). Transcriptional changes are largely thought to
be governed by a handful of so-called EMT Transcription factors
or EMT Tfs (Figure 1) that include the Snail superfamily
(e.g., Snail, Slug, Zeb1/2, Twist 1/2, bHLH and KLF8; reviewed
in Diaz-Lopez et al, 2014). These transcription factors repress the
epithelial programme of gene expression (e.g., E-cadherin) and
enhance mesenchymal expression (e.g., upregulate N-cadherin and
vimentin). Alternative splicing occurs in EMT and changes the
expression pattern of many proteins via factors such as ESRP1/2
and hnRNPM (Ishii et al, 2014; Xu et al, 2014). MiRs are small
non-coding RNA that interact with mRNA and cause silencing
or regulation of transcription (Diaz-Lopez et al, 2014). miRs are
also major players in the EMT process and are a subject of much
research for pancreatic and intestinal cancers, for example,
miR-200 and miR34 (Figure 1 and Diaz-Lopez et al, 2014).
Together these transcriptional and post-transcriptional regulators,
driven by signalling pathways from the microenvironment,
regulate the various programmes that have been described
collectively as EMT, but although there are common threads,
different tissues and environmental conexts can trigger quite
diverse changes associated with loss of epithelial status and gain of
mesenchymal functions.
Downstream of transcriptional changes, alternative splicing and
miRNA regulation, many cytoskeletal proteins are altered in
their expression, localisation or activity. In addition to the
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Figure 1. Involvement of actin cytoskeletal reorganisation in EMT. Epithelial cells make tight junctions (TJ, red) that act as a permeability barrier
between the outside world and the tissue and adherens juncions (AJ) that provide mechanical stability and strength by connections with the actin
cytoskeleton and the transmembrane cadherin proteins. E-cadherins (green) are major scaffold proteins controlling adherens junction integrity and
direct links between E-cadherins and actin nucleating proteins, such as WRC (light blue) and Arp2/3 complex (multicoloured) provide a basis for
sequestering the actin nucleation machinery when cells are non-motile and also for harnessing actin nucleation to provide actin cytoskeletal
scaffolding for tissue integrity. N-WASP (purple) acts with WIRE (not shown) to stabilise and bundle cortical actin filaments (Wu et al, 2014).
Cortactin (orange) is a scaffold, binding both N-WASP and E-cadherin to recruit ARP2/3 and WRC to adherens junctions. EMT can be driven by a
number of signalling pathways (purple boxes, see text for references) that result in the activation of transcriptional programmes and alternative
splicing. In mesenchymal cells, E-cadherin is lost and the actin cytoskeleton undergoes a number of changes, resulting in a shift of actin and its
regulatory proteins and complexes from the cortex towards the leading edge of migrating cells, where they form lamellipodia. A specialised
mesenchymal actin bundling protein, fascin, organises actin filaments at sites of filopodia and is also recruited to invadopodia, the invasive
protrusions of cancer cells, along with Arp2/3 complex, cortactin and N-WASP. These changes are accompanied by the expression of
mesenchymal markers such as N-cadherin, vimentin and fibronectin and a change in cell polarity (from the apico–basal polarity in epithelial cells to
the front–back polarity in mesenchymal cells).
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downregulation of E-cadherin, cells gain the intermediate filament
protein vimentin and change their expression patterns of several
other adhesion molecules such as integrins and cell surface
glycoproteins. They may upregulate other cadherin isoforms, such
as N-cadherin. The actin bundling protein fascin is specifically
expressed in response to the EMT programme in colorectal and
pancreatic cancers (Li et al, 2014) but less is known about its role in
developmental delamination. Cells undergoing EMT also modulate
production of extracellular matrix proteins such as fibronectin
(Chen et al, 2008; Medici et al, 2008). At least in breast cancer,
alternative splicing controls proteins such as the actin-binding
protein Mena, which switches to an invasion promoting form
(Mena-inv) and the membrane receptor CD44 (Goswami et al,
2009; Pignatelli et al, 2014; Xu et al, 2014). The organisation of the
actin cytoskeleton is tightly linked to cell–cell junctions in the
epithelia and this changes dramatically when cells delaminate and
lose their adherens and tight junctions (Figure 1). Many of the
actin filament nucleating proteins are not transcriptionally
regulated, but are differently localised or regulated. For example,
the actin nucleation proteins Scar/WAVE complex, N-WASP,
Arp2/3 complex and cortactin localise to cell–cell junctions in
epithelial cells, but are released from junctions and redirected to
cell-leading edges when cells become mesenchymal (Figure 1).
Many of these changes are controlled by the activity of the Rho-
family small GTPases, including Rac1 and Cdc42, which have both
been implicated in regulating the dynamics of epithelial cell
junctions (Woodham and Machesky, 2014).
EMT AND CELL MIGRATION DURING DEVELOPMENT OF
THE PANCREAS AND INTESTINAL TRACT
EMT first occurs very early in the development of the intestinal
tract. Under the influence of Wnt signalling (Liu et al, 1999) and
downstream mediators belonging to the TGFb superfamily
(Andersson et al, 2007), epiblast cells in the primitive streak of
the embryo undergo EMT, migrating internally to produce the
mesoderm and endoderm. The mechanisms by which this is
orchestrated are reviewed in Chuai et al (2012). The epiblast cells
that do not undergo EMT remain on the surface, forming the
ectoderm (Acloque et al, 2009) and subsequently cells of
the endoderm form an epithelial tube extending for the length
of the embryo. This tube differentiates to form three different
sections – the foregut (gives rise to the pharynx, oesophagus and
stomach), midgut (gives rise to the small intestine and proximal
large intestine) and hindgut (gives rise to the mid and distal large
intestine). At midgestation, the endoderm undergoes further
differentiation in response to signals from the mesoderm and
eventually the intestinal epithelium specialises to form villi and
crypts containing specialised cell types.
In contrast to the intestinal lining, which retains its epithelial
status from the time of formation of the endoderm, some
components of the pancreas and liver require the cells to undergo
a further round of EMT and MET. For example, pancreatic bud
cells undergo EMT and migrate away from the epithelium to form
the endocrine cells of the Islets of Langerhans (Johansson
and Grapin-Botton, 2002). E-cadherin expression is repressed
in a subset of cells, termed neurogenin3þ -expressing insulin-
producing cells, leading to migration and clustering to form islets.
The EMT transcription factor Slug (also called Snail2) inversely
correlates with E-cadherin expression in the developing pancreas
and has been implicated in delamination and migration of the
neurogenin3þ endocrine progenitor cells during islet formation
(Rukstalis and Habener, 2007).
The Rho-family GTPase Cdc42 and its downstream target
N-WASP are key players in pancreatic islet formation,
as the expression of constitutively active Cdc42 prevents
delamination, disassembly of actin at cell–cell junctions and
migration (Kesavan et al, 2014). N-WASP depletion can partially
rescue this phenotype, suggesting that N-WASP-mediated stabili-
sation of junctional actin needs to be repressed for the
delamination process to complete (Kesavan et al, 2009; Kesavan
et al, 2014). Cdc42 is also implicated in the formation of tubules in
the developing pancreas as it has a central role in apical
polarisation and thus lumen formation (Kesavan et al, 2009). In
contrast, Rac1 was implicated in the mobilisation of E-cadherin
junctions in the developing islets, as expression of a dominant
negative Rac1 prevented migration (Greiner et al, 2009).
Under the control of the Rho GTPases, the actin cytoskeleton
has an important role in epithelial cell–cell junctions, providing
connectivity and strength and serving as a platform for signalling
and membrane trafficking. Although next to nothing is known of
the specific roles of the actin nucleation proteins in the intestinal
tract, the key actin organisers N-WASP, cortactin and Arp2/3
complex have all been implicated in actin dynamics at cell–cell
junctions in epithelia in tissue culture systems. Rather than
stimulating new actin polymerisation for protrusion and migra-
tion, as it does in mesenchymal migrating cells, N-WASP functions
together with its binding partner WIRE to stabilise and bundle
actin filaments at cell–cell junctions to allow for generation of
tension by myosin-II (Wu et al, 2014; Figure 1). This junctional
tension can regulate whether cells are integrated or excluded from
the epithelial monolayers, so is an interesting potential contributor
to delamination and extrusion from the epithelium. Ras-trans-
formed cells undergo abnormal extrusion from epithelial tissues
(Hogan et al, 2009) and this may contribute to cancer cells
breaking away from primary tumours and thus gaining access to
other tissues in the body. The actin nucleation-promoting protein
cortactin is implicated as a major scaffold in epithelial cell
junctions, with direct interactions between cortactin, N-WASP and
E-cadherin having a role in recruitment of Arp2/3 complex and the
Scar/WAVE complex, to promote actin nucleation at adherens
junctions (Han et al, 2014; Figure 1). In contrast, N-WASP, Scar/
WAVE proteins, cortactin and Arp2/3 complex localise to leading
edge protrusions of migrating cells, where they contribute to
membrane dynamics and protrusion (Figure 1). Clearly, ancient
proteins involved in motility, such as WASP-family proteins, have
evolved features that allow them to promote epithelial cell
organisation when they need to be restricted from nucleating
leading edge actin assembly and we propose that gaining a deeper
understanding of these features would make a valuable contribu-
tion to our understanding of EMT and cancer spread.
EMT IN CANCERS OF THE INTESTINAL TRACT AND
PANCREAS
EMT has been widely proposed as a mechanism used by carcinoma
cells to regain developmental motile and invasive properties and
disseminate throughout the body. Epithelial tumours usually
initiate by gradually increasing degrees of dysplasia. For example,
colorectal adenocarcinomas usually develop through several benign
stages before becoming malignant. First, there is formation of
aberrant crypt foci (ACFs, abnormal clusters of crypt cells), some
of which may be dysplastic. Continued growth of ACFs results in
formation of benign protrusions of epithelium (polyps). Some
polyps are simply hyperplastic and generally do not advance
beyond this stage. Those containing dysplasia are called adenomas;
if they continue to grow and accumulate additional genetic
abnormalities, they may progress through low-to-high grade
dysplasia and finally to malignant adenocarcinomas (Fearon and
Vogelstein, 1990). How well differentiated a cancer is (how much it
histologically resembles the normal epithelial tissue) has clinical
relevance in terms of prognosis and is expressed in terms of the
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‘grade’ of cancer (Grades 1–3 for colorectal cancer). Likewise,
pancreatic ductal adenocarcinoma is thought to arise by gradual
increases in the dysplasia, which is graded as Pancreatic
Intraepithelial Neoplasia stages 1–3 (Distler et al, 2014). The role
of EMT transcription factors and EMT in these changes is only
partially understood and most of the pancreatic precancerous
lesions in a mouse model of PDAC retained E-cadherin junctions
even though at later stages they expressed the EMT transcription
factor Slug (Li et al, 2014). Human intestinal adenomas contain
hallmarks of some aspects of EMT (Chen et al, 2008).
There is a large body of evidence to suggest that EMT associated
changes in gene expression and cell morphology occur in
carcinomas and that they contribute to the aggressiveness,
invasiveness and spread (Tam and Weinberg, 2013). Studies
investigating the prognostic significance of EMT markers in
human cancers are summarised in Table 1. Two of the most
heavily implicated pathways in cancer EMT are the Wnt and TGFb
signalling pathways. Greater than 80% of all sporadic colorectal
carcinomas harbour mutations in the Wnt signalling pathway,
such as loss of adenomatous polyposis coli (APC) leading to the
constitutive hyperactivation of Wnt signalling. Low E-cadherin
correlates with poor survival in multiple clinical studies and is an
independent prognostic indicator in at least five studies (Table 1).
However, APC loss alone, although it triggers hyperproliferation
and benign tumour formation, is insufficient to drive the
development of cancer; increasing genetic instability is thought
to be another major contributing factor (Bogaert and Prenen,
2014) as is signalling from TGFb and Wnt signalling from the
stroma. EMT is often only apparent at the tumour–stroma
interface in colorectal cancers, because there seems to be a
threshold of signalling necessary to sustain nuclear b-catenin and
to drive invasive behaviour (Brabletz et al, 2001). The cells at the
leading tumour edges frequently show elevation of Zeb1 transcrip-
tion factor (reviewed in Schmalhofer et al (2009)) and Zeb1 is a
Wnt target in colorectal cancer (Sanchez-Tillo et al, 2011) that
correlates with poor survival (Table 1). Zeb1 promotes EMT
changes partly by repression of miR-200 family members ((Burk
et al, 2008) and Table 1). Several miRs have been implicated as
correlating with poor survival in colorectal cancer (Table 1) and
low miR-212 is an independent prognostic indicator of poor
outcome (Table 1). Other EMT transcription factors, Snail1/2
(Slug) and Twist also have been correlated with poor survival in GI
cancers (Table 1) as have hallmarks of EMT such as increased
vimentin and fibronectin (Table 1).
In addition to transcriptional changes, EMT in cancer promotes
similar changes to the cytoskeleton as developmental EMT, with
cell–cell adherens junctions becoming more labile and cell
migration increasing. Although we know almost nothing about
how this works in pancreatic and intestinal cancers, studies from
other cell types might inform future research. For example, in
A431 human squamous carcinoma cells, E-cadherin mobility and
turnover at junctions increases in invading tumours (Serrels et al,
2009). In many cell types, collective invasion, where cells move
together in strands, but maintain some junctional contacts with
neighbours, can be mediated by the loss of E-cadherin and full or
partial replacement with N-cadherin (reviewed recently in Etienne-
Manneville (2014)). N-cadherin promotes mobility and has
recently been found to treadmill along the adjacent side interfaces
between migrating astrocytes to promote collective migration
(Peglion et al, 2014). N-cadherin has been implicated in EMT
changes in colorectal cancer (Hu et al, 2014), so these mechanisms
may be relevant for tumour invasion. In addition to the breakdown
of cell–cell adhesions, proteins such as N-WASP, Scar/WAVE
complex, cortactin and Arp2/3 complex mobilise away from
junctions and towards the leading edges of cells where they actively
induce protrusions that can interact with and remodel the
surrounding stroma (Figure 1 and reviewed in McNiven (2013)).
Actin polymerisation driven by these protein assemblies drives cell
protrusion and migration away from the tumour site. Cells
assemble matrix-degrading structures termed invadopodia that
contain major actin nucleation proteins and that interface with
adhesion and matrix metalloprotease secretion machinery (for
recent reviews, see McNiven(2013); Beaty and Condeelis (2014)).
The actin bundling protein fascin is also a major target of cancer
EMT and is thought to promote invasiveness, migration and
metastatic potential in multiple cancer types, including pancreatic
(Li et al, 2014) and colorectal (Hashimoto et al, 2006). Secretion of
matrix metalloproteases increases during EMT (Ota et al, 2009)
and cells gain the ability to migrate through three-dimensional
(3D) extracellular matrix and to breach tight barriers such as the
basement membranes that surround epithelial organs.
The appearance of tumour buds, or clusters of invaded cells
surrounding a tumour, is a feature particularly associated with
metastasis and poor prognosis in cancers of the gastrointestinal
tract, including colorectal and pancreatic cancer (Park et al, 2005;
Karamitopoulou et al, 2013). These budding cells have many
features that support the hypothesis that they have undergone
EMT, including decrease or loss of E-cadherin, expression of
mesenchymal markers and activation of the Wnt signalling
pathway (Lugli et al, 2012). A recent study of invasive cancers
used 3D reconstruction of serial sections of tumour margins to
demonstrate that human pancreatic, lung, breast and colorectal
cancers invade almost exclusively as collective strands rather than
as individual cells (Bronsert et al, 2014). Tumour buds were
visualised in 3D reconstructions as strands of cells still attached to
the primary tumour that had altered E-cadherin staining, increased
expression of Zeb1 and altered polarity features. It would be
interesting to know how EMT changes in tumour buds correlate
with actin cytoskeletal mobilisation and reorganisation, but this
awaits more advanced imaging methods and cancer models.
We have mostly discussed the role of the actin machinery in
migration of cells away from the primary tumour, but metastasis
involves many steps, including also seeding of escaped tumour cells
in distant sites. Two recent studies highlight the actin cytoskeletal
and integrin-dependent pathways that contribute to seeding of
cancer cells in the lungs and formation of early metastatic nodules
(Shibue et al, 2012; Shibue et al, 2013). The authors identify actin-
rich filopod-like protrusions (FLP) that contain integrin and allow
cells to attach to matrix and activate their prosurvival and growth
pathways via focal adhesion kinase. These FLP structures are
enhanced by the actin nucleation formin protein mDia2 and
regulated by the small GTPase Rif (Shibue et al, 2012). In addition,
FLP are enhanced by expression of the integrin:actin linker protein
b-parvin (Shibue et al, 2013). It is not clear yet whether this
pathway is controlled by cancer associated EMT, but expression of
the EMT transcription factors Twist or Snail or knockdown of
E-cadherin enhanced the FLP pathway, suggesting a potential
connection (Shibue et al, 2013).
SUMMARY
The formation of epithelia by multicellular organisms has required
that cells evolve mechanisms to tightly control protein expression,
activation status and localisation. Most epithelial tissues have some
plasticity in their differentiation status and can convert between
epithelial and mesenchymal if the right signals are given. During
cancer, the EMT programme becomes unregulated or misregulated
to produce changes that resemble type-1 developmental EMT, but
that also have significant differences. Many different signals can
provoke EMT-like changes in cancer that lead to breakdown or
mobilisation of epithelial junctions and enhance the progression
and spread of the cancer. There is a wealth of evidence from the
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clinical literature suggesting a positive correlation between EMT
signalling and transcriptional changes and poor outcome in many
cancers, including those of the pancreas and intestinal tract.
Very little is known about how the motility machinery
reorganises during EMT. Although the loss of E-cadherin junctions
is the most prominent feature of most EMT transitions, many
other changes occur and the actin nucleation-promoting proteins
such as N-WASP, Scar/WAVE and cortactin have specific roles
both in epithelial and mesenchymal cells. Rho-family GTPases
participate in regulation of the actin cytoskeleton in both epithelial
and mesenchymal cells and seem to have important roles in
developmental and cancer-related EMT.
Cancer EMT is clearly very different from developmental EMT,
but parallels exist and EMT-related changes in cancer correlate
strongly with progression and poor outcome. Cancer EMT can be
partial and both solid tumours and circulating tumour cells may
co-express epithelial and mesenchymal markers (Armstrong et al,
2011). Furthermore, the mesenchymal status is not sufficient in all
cases to confer metastasis, as there are some benign tumours
(which by definition, do not usually metastasise) that typically
show aggressive local invasion, for example, giant cell tumour of
the bone (Fletcher et al, 2002) and ameloblastoma (Barnes, 2005).
The importance of EMT in cancer has been challenged (Tarin et al,
2005) and it appears that many tumours that histologically are
‘epithelial’ can be aggressively metastatic. Many questions remain
about which aspects of EMT promote metastatic dissemination
and how cancers hijack developmental EMT to progress. Likewise,
the precise regulation of key actin motility proteins during EMT
and MET is only beginning to be understood and may provide
insight that will be clinically useful.
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